A polyoxomolybdate-based hybrid nano capsule as an antineoplastic agent.
Journal
Nanoscale advances
ISSN: 2516-0230
Titre abrégé: Nanoscale Adv
Pays: England
ID NLM: 101738708
Informations de publication
Date de publication:
07 Nov 2023
07 Nov 2023
Historique:
received:
27
06
2023
accepted:
30
09
2023
medline:
9
11
2023
pubmed:
9
11
2023
entrez:
9
11
2023
Statut:
epublish
Résumé
Polyoxometalates (POMs) are versatile anionic clusters which have attracted a lot of attention in biomedical investigations. To counteract the increasing resistance effect of cancer cells and the high toxicity of chemotherapeutic treatments, POM-based metallodrugs can be strategically synthesized by adjusting the stereochemical and physicochemical features of POMs. In the present report a polyoxomolybdate (POMo) based organic-inorganic hybrid solid (C
Identifiants
pubmed: 37941962
doi: 10.1039/d3na00459g
pii: d3na00459g
pmc: PMC10628982
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6045-6052Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Angew Chem Int Ed Engl. 2023 Aug 1;62(31):e202303817
pubmed: 37098776
Spectrochim Acta A Mol Biomol Spectrosc. 2013 Aug;112:78-83
pubmed: 23659953
Angew Chem Int Ed Engl. 2020 Nov 16;59(47):20779-20793
pubmed: 32633859
Dalton Trans. 2018 May 15;47(19):6645-6653
pubmed: 29632935
Anticancer Res. 2019 Apr;39(4):1839-1847
pubmed: 30952724
Cancers (Basel). 2020 Apr 23;12(4):
pubmed: 32340362
Dalton Trans. 2017 Feb 28;46(9):2874-2883
pubmed: 28245011
Front Genet. 2015 Apr 23;6:157
pubmed: 25954303
Chemistry. 2021 Apr 12;27(21):6422-6434
pubmed: 33314442
J Photochem Photobiol B. 2013 Jul 5;124:27-33
pubmed: 23648797
Tohoku J Exp Med. 1992 Oct;168(2):421-6
pubmed: 1306330
Dalton Trans. 2020 Jun 7;49(21):7069-7077
pubmed: 32400784
Chem Commun (Camb). 2017 Nov 28;53(95):12810-12813
pubmed: 29143019
Int J Mol Sci. 2023 Mar 06;24(5):
pubmed: 36902473
J Indian Med Assoc. 1965 May 1;44:477-9
pubmed: 14299045
Dalton Trans. 2013 Jul 21;42(27):9914-20
pubmed: 23695527
J Biol Inorg Chem. 2022 Aug;27(4-5):405-419
pubmed: 35713714
ACS Appl Mater Interfaces. 2023 Mar 8;15(9):11853-11865
pubmed: 36847791
Dalton Trans. 2021 Feb 2;50(4):1253-1260
pubmed: 33410831
Angew Chem Int Ed Engl. 2019 Mar 4;58(10):2980-2999
pubmed: 29893459
Chem Commun (Camb). 2018 Jan 31;54(10):1153-1169
pubmed: 29355262
Talanta. 2011 Oct 15;85(5):2265-89
pubmed: 21962644
Coord Chem Rev. 2015 Sep 1;299:22-38
pubmed: 26339074
Molecules. 2022 May 05;27(9):
pubmed: 35566295
Chem Soc Rev. 2012 Nov 21;41(22):7384-402
pubmed: 22850732
J Cancer Sci Ther. 2019;11(4):
pubmed: 32148661
Dalton Trans. 2014 Apr 21;43(15):5840-6
pubmed: 24577152
Chem Rev. 1998 Feb 5;98(1):327-358
pubmed: 11851509
Nat Commun. 2014 Mar 04;5:3422
pubmed: 24595206
Crit Rev Oncol Hematol. 2020 Jun;150:102972
pubmed: 32344317
ChemMedChem. 2014 Dec;9(12):2791-7
pubmed: 25209896
ACS Omega. 2017 Sep 11;2(9):5684-5690
pubmed: 31457829
Inorg Chem. 2021 Jan 4;60(1):28-31
pubmed: 33332970
J Mater Chem B. 2020 Sep 23;8(36):8189-8206
pubmed: 32812616
Mol Cell. 2003 Apr;11(4):987-96
pubmed: 12718884
Anticancer Res. 2015 Apr;35(4):2077-84
pubmed: 25862863
Sci Rep. 2016 Apr 25;6:24759
pubmed: 27108955
Angew Chem Int Ed Engl. 2023 Aug 7;62(32):e202303290
pubmed: 37132602
Nanoscale Adv. 2022 Oct 13;4(23):5015-5020
pubmed: 36504740
Mol Biosyst. 2015 Feb;11(2):522-31
pubmed: 25424306
Biomed Pharmacother. 2006 Aug;60(7):353-8
pubmed: 16860528
Medchemcomm. 2017 Apr 27;8(6):1283-1296
pubmed: 30108839
J Natl Cancer Inst. 1974 Aug;53(2):469-74
pubmed: 4367244
Bioorg Med Chem Lett. 2013 Mar 1;23(5):1462-6
pubmed: 23337597
JACS Au. 2023 Feb 13;3(4):978-990
pubmed: 37124292
ACS Appl Bio Mater. 2020 Jul 20;3(7):4025-4035
pubmed: 35025477
Nucleosides Nucleotides Nucleic Acids. 2010 Nov;29(11):854-66
pubmed: 21128172
Chem Sci. 2022 Nov 16;14(1):10-28
pubmed: 36605748
J Phys Chem B. 2012 Jan 12;116(1):639-45
pubmed: 22128894
Chem Soc Rev. 2020 Jan 21;49(2):382-432
pubmed: 31793568